News

Company Enters into Collaborative Research Agreement with NIAID and Company to Run Phase 2a/b Trials in EU BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), an endogenous human protein that simultaneously modulates inflammation and boosts immune function announced that its recently closed convertible note round was oversubscribed by investors. Read article […]

Data to Further Inform Design of Phase 2 Studies BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) December, 2014 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting plasma gelsolin’s (pGSN) role in immune function announced that it has established collaborations with Vanderbilt and Northwestern Universities to analyze plasma gelsolin levels in a well-adjudicated population of

Recombinant human plasma gelsolin has demonstrated efficacy against both gram positive and gram negative bacteria. This adds to our broad geographic coverage, including a patent granted last year in China. BioAegis is pursuing worldwide patent filings for infectious disease.

Initial Funding Effort to Advance Recombinant Plasma Gelsolin Therapy into Human Trials BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December 3, 2014) BioAegis Therapeutics announces that it has closed its final tranche of an $8MM convertible note round. These funds will be used to advance its clinical program into human clinical trials in severe

Patent Covers Therapeutic Uses of Plasma Gelsolin in Renal Failure BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December 3, 2014) BioAegis Therapeutics announces that its portfolio of patents has been expanded with the granting of a second European Patent for plasma gelsolin. Claims in this patent are directed to the treatment of renal failure.

Initial Effort to Elucidate the Role of Plasma Gelsolin in Human Diseases with Significant Inflammatory and Infectious Disease Complications BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2014) BioAegis Therapeutics has announced that it has entered into a research collaboration with the National Institute of Allergy and Infectious Diseases. NIAID, which is one

Company To Sponsor Phase 2 Trials in Community-Acquired Pneumonia in Europe BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2014) BioAegis Therapeutics reports that its clinical program was well-­received by two EU regulatory authorities, the MHRA in the United Kingdom and the MPA in Sweden. After completion of required preparatory work the company

Company to enter Full-Scale cGMP Production for Clinical Trials BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – March 4, 2013) BioAegis Therapeutics announced today it has completed its engineering manufacturing run and is preparing to launch its manufacture of clinical supplies. The campaign to produce recombinant protein in E. coli was successful and generated higher

Company to Manufacture Clinical-Grade Supplies for Forthcoming Clinical Trial in Community-Acquired Pneumonia BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 26, 2013) BioAegis Therapeutics announced that it has engaged Debra Barngrover Ph.D. to oversee the company’s recombinant manufacturing of plasma gelsolin. Dr. Barngrover is a pharmaceutical process development expert with extensive experience in protein

Company to Evaluate Orphan Diseases as Secondary Indications BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – July 28, 2013) BioAegis Therapeutics announced that the FDA has transferred Orphan Designations for cystic fibrosis and bronchiectasis to the company. The FDA Office of Orphan Products Development (OOPD) provides support and incentives for sponsors to develop products for